Year in review 2007: Critical Care - Multiple organ failure and sepsis

Critical Care

Volumn 12, Issue 5, 2008, Pages

  O'Brien Jr , James M ^a   Ali, Naeem A ^a   Abraham, Edward ^b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DEFENSIN 2; BIOLOGICAL MARKER; DROTRECOGIN; GLUTAMINE; HIGH MOBILITY GROUP B1 PROTEIN; LIPOPOLYSACCHARIDE BINDING PROTEIN; POLYMYXIN B; PROCALCITONIN;

ACALCULOUS CHOLECYSTITIS; APOPTOSIS; CLINICAL PRACTICE; CRITICALLY ILL PATIENT; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; EXOSOME; GENE EXPRESSION REGULATION; HEMOPERFUSION; HOSPITAL INFECTION; HUMAN; IMMUNE RESPONSE; INFECTION RISK; INNATE IMMUNITY; INTENSIVE CARE; MULTIPLE ORGAN FAILURE; NONHUMAN; OXYGEN SATURATION; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RESUSCITATION; REVIEW; SEPSIS; SEPTIC SHOCK; ANIMAL; METHODOLOGY;

ANIMALS; CRITICAL CARE; HUMANS; MULTIPLE ORGAN FAILURE; SEPSIS;

EID: 55049116440     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc6950     Document Type: Review

References (60)

1. Vakkala M Laurila JJ Saarnio J Koivukangas V Syrjala H Karttunen T Soini Y Ala-Kokko TI Cellular turnover and expression of hypoxic-inducible factor in acute acalculous and calculous cholecystitis Crit Care 2007, 11:R116. 2556769 17974017
2. Ke Q Costa M Hypoxia-inducible factor-1 (HIF-1) Mol Pharmacol 2006, 70:1469-1480. 16887934
3. Vincent JL Sakr Y Sprung CL Ranieri VM Reinhart K Gerlach H Moreno R Carlet J Le Gall JR Payen D Sepsis in European intensive care units: results of the SOAP study Crit Care Med 2006, 34:344-353. 16424713
4. Engel C Brunkhorst FM Bone HG Brunkhorst R Gerlach H Grond S Gruendling M Huhle G Jaschinski U John S Mayer K Oppert M Olthoff D Quintel M Ragaller M Rossaint R Stuber F Weiler N Welte T Bogatsch H Hartog C Loeffler M Reinhart K Epidemiology of sepsis in Germany: Results from a national prospective multicenter study Intensive Care Med 2007, 33:606-618. 17323051
5. Hotchkiss RS Karl IE The pathophysiology and treatment of sepsis N Engl J Med 2003, 348:138-150. 12519925
6. Sriskandan S Altmann DM The immunology of sepsis J Pathol 2008, 214:211-223. 18161754
7. Boman HG Antibacterial peptides: Basic facts and emerging concepts J Intern Med 2003, 254:197-215. 12930229
8. Yang D Biragyn A Kwak LW Oppenheim JJ Mammalian defensins in immunity: more than just microbicidal Trends Immunol 2002, 23:291-296. 12072367
9. Book M Chen Q Lehmann LE Klaschik S Weber S Schewe JC Luepertz M Hoeft A Stuber F Inducibility of the endogenous antibiotic peptide beta-defensin 2 is impaired in patients with severe sepsis Crit Care 2007, 11:R19. 2151902 17302973
10. Brodsky SV Zhang F Nasjletti A Goligorsky MS Endothelium-derived microparticles impair endothelial function in vitro Am J Physiol Heart Circ Physiol 2004, 286:H1910-H1915. 15072974
11. Meziani F Tesse A Andriantsitohaina R Microparticles are vectors of paradoxical information in vascular cells including the endothelium: role in health and diseases Pharmacol Rep 2008, 60:75-84. 18276988
12. Piccin A Murphy WG Smith OP Circulating microparticles: Pathophysiology and clinical implications Blood Rev 2007, 21:157-171. 17118501
13. Janiszewski M Do Carmo AO Pedro MA Silva E Knobel E Laurindo FR Platelet-derived exosomes of septic individuals possess proapoptotic NAD(P)H oxidase activity: A novel vascular redox pathway Crit Care Med 2004, 32:818-825. 15090968
14. Gambim MH do Carmo AO Marti L Verissimo-Filho S Lopes LR Janiszewski M Platelet-derived exosomes induce endothelial cell apoptosis through peroxynitrite generation: Experimental evidence for a novel mechanism of septic vascular dysfunction Crit Care 2007, 11:R107. 2556756 17894858
15. Azevedo LC Janiszewski M Soriano FG Laurindo FR Redox mechanisms of vascular cell dysfunction in sepsis Endocr Metab Immune Disord Drug Targets 2006, 6:159-164. 16787290
16. Wang H Bloom O Zhang M Vishnubhakat JM Ombrellino M Che J Frazier A Yang H Ivanova S Borovikova L Manogue KR Faist E Abraham E Andersson J Andersson U Molina PE Abumrad NN Sama A Tracey KJ HMG-1 as a late mediator of endotoxin lethality in mice Science 1999, 285:248-251. 10398600
17. Parrish W Ulloa L High-mobility group box-1 isoforms as potential therapeutic targets in sepsis Methods Mol Biol 2007, 361:145-162. 17172710
18. Wang H Li W Goldstein R Tracey KJ Sama AE HMGB1 as a potential therapeutic target Novartis Found Symp 2007, 280:73-85. 17380789
19. Zweigner J Schumann RR Weber JR The role of lipopolysaccharide-binding protein in modulating the innate immune response Microbes Infect 2006, 8:946-952. 16483818
20. Assicot M Gendrel D Carsin H Raymond J Guilbaud J Bohuon C High serum procalcitonin concentrations in patients with sepsis and infection Lancet 1993, 341:515-518. 8094770
21. Gaini S Koldkjaer OG Moller HJ Pedersen C Pedersen SS A comparison of high-mobility group-box 1 protein, lipopolysaccharide-binding protein and procalcitonin in severe community-acquired infections and bacteraemia: A prospective study Crit Care 2007, 11:R76. 2206511 17625012
22. Nobre V Harbarth S Graf JD Rohner P Pugin J Use of procalcitonin to shorten antibiotic treatment duration in septic patients: A randomized trial Am J Respir Crit Care Med 2008, 177:498-505. 18096708
23. Ibrahim EH Sherman G Ward S Fraser VJ Kollef MH The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting Chest 2000, 118:146-155. 10893372
24. Kumar A Roberts D Wood KE Light B Parrillo JE Sharma S Suppes R Feinstein D Zanotti S Taiberg L Gurka D Kumar A Cheang M Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock Crit Care Med 2006, 34:1589-1596. 16625125
25. 2 Collaborative Group N Engl J Med 1995, 333:1025-1032. 7675044
26. Heyland DK Cook DJ King D Kernerman P Brun-Buisson C Maximizing oxygen delivery in critically ill patients: A methodologic appraisal of the evidence Crit Care Med 1996, 24:517-524. 8625644
27. Rivers E Nguyen B Havstad S Ressler J Muzzin A Knoblich B Peterson E Tomlanovich M Early goal-directed therapy in the treatment of severe sepsis and septic shock N Engl J Med 2001, 345:1368-1377. 11794169
28. McIntyre LA Hebert PC Fergusson D Cook DJ Aziz A A survey of Canadian intensivists' resuscitation practices in early septic shock Crit Care 2007, 11:R74. 2206518 17623059
29. Hebert PC Wells G Blajchman MA Marshall J Martin C Pagliarello G Tweeddale M Schweitzer I Yetisir E A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group N Engl J Med 1999, 340:409-417. 9971864
30. Raghavan M Marik PE Anemia, allogenic blood transfusion, and immunomodulation in the critically ill Chest 2005, 127:295-307. 15653997
31. Brunkhorst FM Engel C Bloos F Meier-Hellmann A Ragaller M Weiler N Moerer O Gruendling M Oppert M Grond S Olthoff D Jaschinski U John S Rossaint R Welte T Schaefer M Kern P Kuhnt E Kiehntopf M Hartog C Natanson C Loeffler M Reinhart K German Competence Network Sepsis (SepNet) Intensive insulin therapy and pentastarch resuscitation in severe sepsis N Engl J Med 2008, 358:125-139. 18184958
32. Evidence-based colloid use in the critically ill: American Thoracic Society Consensus Statement Am J Respir Crit Care Med 2004, 170:1247-1259. 15563641
33. Barron ME Wilkes MM Navickis RJ A systematic review of the comparative safety of colloids Arch Surg 2004, 139:552-563. 15136357
34. Ouderkirk JP Nord JA Turett GS Kislak JW Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria Antimicrob Agents Chemother 2003, 47:2659-2662. 166058 12878536
35. Cruz DN Perazella MA Bellomo R de Cal M Polanco N Corradi V Lentini P Nalesso F Ueno T Ranieri VM Ronco C Effectiveness of polymyxin B-immobilized fiber column in sepsis: A systematic review Crit Care 2007, 11:R47. 2206475 17448226
36. Bernard GR Vincent JL Laterre PF LaRosa SP Dhainaut JF Lopez-Rodriguez A Steingrub JS Garber GE Helterbrand JD Ely EW Fisher CJ Jr Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med 2001, 344:699-709. 11236773
37. Sprung CL Annane D Keh D Moreno R Singer M Freivogel K Weiss YG Benbenishty J Kalenka A Forst H Laterre PF Reinhart K Cuthbertson BH Payen D Briegel J CORTICUS Study Group Hydrocortisone therapy for patients with septic shock N Engl J Med 2008, 358:111-124. 18184957
38. Wischmeyer PE Lynch J Liedel J Wolfson R Riehm J Gottlieb L Kahana M Glutamine administration reduces Gram-negative bacteremia in severely burned patients: A prospective, randomized, double-blind trial versus isonitrogenous control Crit Care Med 2001, 29:2075-2080. 11700398
39. Wischmeyer PE Kahana M Wolfson R Ren H Musch MM Chang EB Glutamine reduces cytokine release, organ damage, and mortality in a rat model of endotoxemia Shock 2001, 16:398-402. 11699081
40. Singleton KD Serkova N Banerjee A Meng X Gamboni-Robertson F Wischmeyer PE Glutamine attenuates endotoxin-induced lung metabolic dysfunction: potential role of enhanced heat shock protein 70 Nutrition 2005, 21:214-223. 15723751
41. Lindquist S Craig EA The heat-shock proteins Annu Rev Genet 1988, 22:631-677. 2853609
42. Ang D Liberek K Skowyra D Zylicz M Georgopoulos C Biological role and regulation of the universally conserved heat shock proteins J Biol Chem 1991, 266:24233-24236. 1761528
43. Jing L Wu Q Wang F Glutamine induces heat-shock protein and protects against Escherichia coli lipopolysaccharide-induced vascular hyporeactivity in rats Crit Care 2007, 11:R34. 2206450 17346354
44. Quartin AA Schein RM Kett DH Peduzzi PN Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group JAMA 1997, 277:1058-1063. 9091694
45. Graf J Koch M Dujardin R Kersten A Janssens U Health-related quality of life before, 1 month after, and 9 months after intensive care in medical cardiovascular and pulmonary patients Crit Care Med 2003, 31:2163-2169. 12973175
46. Granja C Dias C Costa-Pereira A Sarmento A Quality of life of survivors from severe sepsis and septic shock may be similar to that of others who survive critical illness Crit Care 2004, 8:R91-R98. 420036 15025783
47. Korosec JH Jagodic K Podbregar M Long-term outcome and quality of life of patients treated in surgical intensive care: A comparison between sepsis and trauma Crit Care 2006, 10:R134. 1751058 16978417
48. Erickson SE Martin GS Effect of sepsis therapies on health-related quality of life Crit Care 2008, 12:109. 2374612 18254930
49. Garcia LF Peres BD De Cubber M Vincent JL Long-term outcome in ICU patients: What about quality of life? Intensive Care Med 2003, 29:1286-1293. 12851765
50. Longo CJ Heyland DK Fisher HN Fowler RA Martin CM Day AG A long-term follow-up study investigating health-related quality of life and resource use in survivors of severe sepsis: Comparison of recombinant human activated protein C with standard care Crit Care 2007, 11:R128. 2246225 18072978
51. Herridge MS Long-term outcomes after critical illness: Past, present, future Curr Opin Crit Care 2007, 13:473-475. 17762221
52. Herridge MS Cheung AM Tansey CM Matte-Martyn A Diaz-Granados N Al-Saidi F Cooper AB Guest CB Mazer CD Mehta S Stewart TE Barr A Cook D Slutsky AS Canadian Critical Care Trials Group One-year outcomes in survivors of the acute respiratory distress syndrome N Engl J Med 2003, 348:683-693. 12594312
53. Herridge MS Long-term outcomes after critical illness Curr Opin Crit Care 2002, 8:331-336. 12386494
54. Banks SM Gerstenberger E Eichacker PQ Natanson C Long-term cost effectiveness of drotrecogin alfa (activated): An unanswered question Crit Care Med 2003, 31:308-309. 12545035
55. Angus DC Linde-Zwirble WT Clermont G Ball DE Basson BR Ely EW Laterre PF Vincent JL Bernard G van Hout B Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis Crit Care Med 2003, 31:1-11. 12544986
56. Davies A Ridley S Hutton J Chinn C Barber B Angus DC Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom Anaesthesia 2005, 60:155-162. 15644013
57. Neilson AR Burchardi H Chinn C Clouth J Schneider H Angus D Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany J Crit Care 2003, 18:217-227. 14691895
58. Frampton JE Foster RH Drotrecogin alfa (activated): A pharmacoeconomic review of its use in severe sepsis Pharmacoeconomics 2004, 22:445-476. 15137883
59. Green C Dinnes J Takeda AL Cuthbertson BH Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom Int J Technol Assess Health Care 2006, 22:90-100. 16673685
60. Manns BJ Lee H Doig CJ Johnson D Donaldson C An economic evaluation of activated protein C treatment for severe sepsis N Engl J Med 2002, 347:993-1000. 12324556